Holen Sie sich die Stockscreener-App
1.12
0.90%
0.01
Schlusskurs vom Vortag:
$1.11
Offen:
$1.11
24-Stunden-Volumen:
1.47M
Relative Volume:
0.89
Marktkapitalisierung:
$430.71M
Einnahmen:
$106.34M
Nettoeinkommen (Verlust:
$-74.66M
KGV:
-1.1789
EPS:
-0.95
Netto-Cashflow:
$-46.12M
1W Leistung:
-11.11%
1M Leistung:
-31.29%
6M Leistung:
-14.50%
1J Leistung:
-15.79%
1-Tages-Spanne:
$1.11
$1.165
1-Wochen-Bereich:
$1.10
$1.28
52-Wochen-Spanne:
$0.92
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Firmenname
Standard Biotools Inc
Sektor
Branche
Telefon
(650) 266-6000
Adresse
2 TOWER PLACE, SOUTH SAN FRANCISCO
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
1.12 | 426.87M | 106.34M | -74.66M | -46.12M | -0.95 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-27 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | Eingeleitet | TD Cowen | Buy |
| 2024-04-04 | Eingeleitet | Jefferies | Buy |
| 2023-07-12 | Eingeleitet | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Aktie (LAB) Neueste Nachrichten
Illumina completes acquisition of SomaLogic from Standard BioTools - BizWest
Standard BioTools Inc. (LAB) Stock Analysis: Unpacking a 39.64% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Can Standard BioTools Inc. (FLB) stock survive global slowdownFed Meeting & Weekly Setup with ROI Potential - mfd.ru
Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Can Standard BioTools Inc. stock outperform in a bear marketSwing Trade & Community Trade Idea Sharing Platform - mfd.ru
Will Standard BioTools Inc. stock recover after earningsJuly 2025 Retail & Reliable Trade Execution Plans - mfd.ru
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Yahoo Finance
Swing Trade: Will BayFirst Financial Corp benefit from geopolitical trends2025 Valuation Update & Weekly High Conviction Ideas - baoquankhu1.vn
Market Outlook: Can Standard BioTools Inc stock outperform in a bear market2025 Top Gainers & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Standard BioTools Strengthens Balance Sheet with Major Divestiture - AD HOC NEWS
Aug Patterns: Is Standard BioTools Inc impacted by rising ratesJuly 2025 Technicals & Weekly Market Pulse Alerts - baoquankhu1.vn
Market Pulse: Will Standard BioTools Inc stock recover after earnings2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Illumina completes acquisition of SomaLogic - marketscreener.com
Weekly Earnings: How volatile is Standard BioTools Inc stockJuly 2025 Chart Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Standard BioTools completes sale of SomaLogic to Illumina for $350 million - Investing.com Nigeria
Standard BioTools Inc. (LAB) Stock Analysis: Navigating Challenges with a 9.93% Potential Upside - DirectorsTalk Interviews
Standard BioTools (LAB) Concludes Sale of SomaLogic for $425 Mil - GuruFocus
Standard BioTools Completes Major Proteomics Business Divestiture - TipRanks
Standard BioTools Completes Sale of SomaLogic to Illumina - citybiz
Standard BioTools Inc. Completes $350 Million Sale of SomaLogic to Illumina, Enhancing Financial Position for Growth Strategy - Quiver Quantitative
Illumina (NASDAQ: ILMN) completes $350M SomaLogic proteomics deal - Stock Titan
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation - simplywall.st
Aug Reactions: Is Paramount Global stock risky to hold now2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Standard BioTools (NASDAQ:LAB) versus Clover Health Investments (NASDAQ:CLOV) Critical Review - Defense World
Chipmakers Recap: Can Standard BioTools Inc stock double in the next yearJuly 2025 Highlights & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Aug Outlook: Will Standard BioTools Inc stock recover after earningsPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago - Yahoo Finance
Death Cross: Is Sunshine Biopharma Incs ROE strong enoughEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
The Truth About SomaLogic Inc: Is This Quiet Biotech About To Blow Up Or Fade Out? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Sells 773,708 Shares of Standard BioTools Inc. $LAB - MarketBeat
SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools - Intellectia AI
Standard BioTools Inc. (LAB) Stock Analysis: Navigating a Challenging Market with Innovative Technologies - DirectorsTalk Interviews
Sentiment Recap: Why Standard BioTools Inc stock could rally in 20252025 Growth vs Value & Trade Opportunity Analysis - Bộ Nội Vụ
Standard BioTools (NASDAQ:LAB) Trading 5.6% HigherStill a Buy? - MarketBeat
Illumina Announces Preliminary Unaudited Financial Results for Q4 and Fiscal Year 2025 - TradingView
Why Standard BioTools Inc. stock could outperform in 2025Market Growth Summary & AI Powered Market Trend Analysis - ulpravda.ru
Will Standard BioTools Inc. stock benefit from green energy trendsPortfolio Risk Report & Reliable Intraday Trade Alerts - Улправда
User | woonsocketcall.comStandard BioTools Inc.Common Stock (Nasdaq:LAB) Stock Quote - FinancialContent
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue - Sahm
Can Standard BioTools Inc. stock maintain operating marginsLayoff News & Expert-Curated Trade Recommendations - Улправда
Will Standard BioTools Inc. (FLB) stock rise with strong economyJuly 2025 Catalysts & Low Risk High Reward Ideas - Улправда
Is Standard BioTools Inc. stock a buy before product launchesMarket Risk Summary & High Accuracy Investment Signals - ulpravda.ru
Standard BioTools (NASDAQ:LAB) Shares Gap UpShould You Buy? - MarketBeat
Standard BioTools Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2025 - marketscreener.com
Standard BioTools Reports Preliminary Q4, Full-Year Revenue - Nasdaq
Standard BioTools (NASDAQ:LAB) & Hinge Health (NYSE:HNGE) Critical Contrast - Defense World
What analysts say about Standard BioTools Inc stockExit Strategy Tips & Investment Portfolio Recommendations - earlytimes.in
User | theeveningleader.comStandard BioTools Inc.Common Stock (Nasdaq:LAB) Stock Quote - markets.financialcontent.com
Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80% - simplywall.st
Standard BioTools: Outlook Still Murky (NASDAQ:LAB) - Seeking Alpha
Finanzdaten der Standard Biotools Inc-Aktie (LAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Standard Biotools Inc-Aktie (LAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L | Director |
Dec 02 '25 |
Buy |
1.42 |
125,000 |
177,512 |
71,875,000 |
| Casdin Partners Master Fund, L | Director |
Dec 03 '25 |
Buy |
1.44 |
75,000 |
108,037 |
71,950,000 |
| Casdin Partners Master Fund, L | Director |
Nov 25 '25 |
Buy |
1.30 |
7,550,000 |
9,838,405 |
71,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 24 '25 |
Buy |
1.43 |
150,000 |
214,875 |
64,200,000 |
| Casdin Partners Master Fund, L | Director |
Nov 20 '25 |
Buy |
1.30 |
450,000 |
586,260 |
64,050,000 |
| Casdin Partners Master Fund, L | Director |
Nov 19 '25 |
Buy |
1.28 |
350,000 |
448,910 |
63,600,000 |
| Casdin Partners Master Fund, L | Director |
Nov 18 '25 |
Buy |
1.23 |
275,000 |
339,405 |
63,250,000 |
| Casdin Partners Master Fund, L | Director |
Nov 13 '25 |
Buy |
1.20 |
450,000 |
541,395 |
62,500,000 |
| Casdin Partners Master Fund, L | Director |
Nov 14 '25 |
Buy |
1.24 |
250,000 |
309,800 |
62,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 17 '25 |
Buy |
1.22 |
225,000 |
275,580 |
62,975,000 |
1.33%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):